GRI Bio, Inc.
Business
GRI Bio is a clinical-stage biopharmaceutical company discovering and developing therapies targeting dysregulated immune responses in inflammatory, fibrotic, and autoimmune disorders. Its lead candidate GRI-0621, an oral iNKT cell inhibitor, is in Phase 2a for idiopathic pulmonary fibrosis. GRI-0803, a dNKT cell activator, targets systemic lupus erythematosus and related autoimmune conditions. The company retains global development and commercialization rights to all product candidates.
Summary from 10-K filed 2026-01-30
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Research and development | 7 | 4 | 3 | 242,000 | 5 | |
| General and administrative | 5 | 4 | 8 | 2 | 4 | |
| Total operating expenses | 12 | 8 | 11 | 2 | 9 | |
| Loss from operations | −12 | −8 | −11 | −2 | −9 | |
| Change in fair value of warrant liability | 0 | 3,000 | 182,000 | 0 | — | |
| Interest income | 21,000 | 25,000 | −2 | −653,000 | −16,000 | |
| Net loss | −12 | −8 | −13 | −3 | −9 | |
| Deemed dividend on Series B Warrants | 0 | −2 | 0 | — | — | |
| Net loss available to common stockholders | −12 | −10 | −13 | — | — | |
| Net loss per share of common stock, basic (in usd per share) | −121.8 | −1,546 | −5,018 | −24.95 | −1.42 | |
| Net loss per share of common stock, diluted (in usd per share) | −121.8 | −1,546 | −5,018 | −24.95 | −1.42 | |
| Weighted-average common shares outstanding, basic (in shares) | 98,162 | 6,547 | 2,598 | 128,994 | 7 | |
| Weighted-average common shares outstanding, diluted (in shares) | 98,162 | 6,547 | 2,598 | 128,994 | 7 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 8 | 5 | 2 | 9,000 | 4 | |
| Prepaid expenses and other current assets | 363,000 | 587,000 | 1 | 303,000 | 619,000 | |
| Total current assets | 9 | 6 | 3 | 312,000 | 8 | |
| Property and equipment, net | 3,000 | 4,000 | 8,000 | 4,000 | 0 | |
| Operating lease right-of-use assets | 71,000 | 120,000 | 14,000 | 67,000 | — | |
| Total assets | 9 | 6 | 3 | 383,000 | 8 | |
| Accounts payable | 2 | 897,000 | 1 | 1 | 918,000 | |
| Accrued expenses | 750,000 | 691,000 | 1 | 36,000 | 1 | |
| Operating lease liabilities, current | 56,000 | 48,000 | 14,000 | 57,000 | — | |
| Total current liabilities | 3 | 2 | 3 | 2 | 2 | |
| Operating lease liabilities, non-current | 15,000 | 71,000 | 0 | 14,000 | — | |
| Total liabilities | 3 | 2 | 3 | 2 | 3 | |
| Commitments and contingencies (Note 10) | — | — | — | — | — | |
| Common stock, $0.0001 par value; 250,000,000 shares authorized; 497,693 and 18,768 shares issued and outstanding as of December 31, 2025 and 2024, respectively | 0 | 0 | 0 | 0 | 0 | |
| Additional paid-in-capital | 58 | 44 | 32 | 17 | 28 | |
| Accumulated deficit | −52 | −40 | −32 | −18 | −22 | |
| Total stockholders' equity | 6 | 4 | 259,000 | −2 | −5 | |
| Total liabilities and stockholders' equity | 9 | 6 | 3 | 383,000 | 8 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Depreciation expense | 4,000 | 4,000 | 4,000 | 3,000 | — | |
| Stock-based compensation expense | 793,000 | 148,000 | 388,000 | 25,000 | 626,000 | |
| Change in fair value of warrant liability | 0 | −3,000 | −182,000 | 0 | — | |
| Change in operating lease right of use assets | 48,000 | — | 53,000 | 47,000 | — | |
| Change in operating lease right of use assets | — | −105,000 | — | — | — | |
| Prepaid expenses and other current assets | 251,000 | 313,000 | −547,000 | −35,000 | −55,000 | |
| Accounts payable | 663,000 | −387,000 | 2 | 897,000 | −308,000 | |
| Accrued expenses | 59,000 | −479,000 | 125,000 | 696,000 | 583,000 | |
| Operating lease liabilities | −48,000 | 105,000 | −57,000 | −43,000 | — | |
| Cash used in operating activities | −10 | −9 | −9 | −1 | −8 | |
| Purchase of property and equipment | −3,000 | 0 | −8,000 | −3,000 | 0 | |
| Cash used in investing activities | −3,000 | 0 | −8,000 | −3,000 | −4 | |
| Proceeds from warrant exercise | 0 | 762,000 | 12,000 | 0 | — | |
| Payment for fractional shares in connection with reverse stock split | −1,000 | −1,000 | 0 | — | — | |
| Payment of deferred stock issuance costs | −2 | −2 | −517,000 | −111,000 | — | |
| Cash provided by financing activities | 13 | 12 | 11 | 1 | 16 | |
| Net increase in cash and cash equivalents | 3 | 3 | 2 | −81,000 | 4 | |
| Stock issuance costs included in accounts payable | 278,000 | 0 | 226,000 | 340,000 | — | |
| Issuance of warrants for payment of stock issuance costs | 440,000 | 287,000 | 18,000 | 0 | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is GRI Bio, Inc.'s CIK number?
GRI Bio, Inc.'s SEC CIK number is 0001824293 (1824293). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find GRI Bio, Inc.'s SEC filings?
All of GRI Bio, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did GRI Bio, Inc. last report earnings?
GRI Bio, Inc. (GRI) most recently filed an earnings 8-K with the SEC on May 14, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001824293-26-000046). This is GRI Bio, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is GRI Bio, Inc.'s most recent earnings 8-K?
GRI Bio, Inc.'s latest earnings 8-K (Item 2.02) was filed May 14, 2026 under accession 0001824293-26-000046. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View GRI Bio, Inc.'s latest earnings 8-K →
Look up any company's CIK number →